EquityIndex FundsVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹160 Cr
Expense Ratio
0.50%
ISIN
INF754K01LV5
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+11.88%
— (Cat Avg.)
3 Years
+14.38%
— (Cat Avg.)
Since Inception
+15.63%
— (Cat Avg.)
Equity | ₹159.13 Cr | 99.60% |
Others | ₹0.64 Cr | 0.40% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹20.23 Cr | 12.66% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹10.21 Cr | 6.39% |
Cipla Ltd | Equity | ₹9.17 Cr | 5.74% |
Eli Lilly and Co | Equity | ₹8.83 Cr | 5.53% |
Dr Reddy's Laboratories Ltd | Equity | ₹8.2 Cr | 5.14% |
Divi's Laboratories Ltd | Equity | ₹8.19 Cr | 5.12% |
Apollo Hospitals Enterprise Ltd | Equity | ₹8 Cr | 5.01% |
Lupin Ltd | Equity | ₹5.73 Cr | 3.58% |
Johnson & Johnson | Equity | ₹5.03 Cr | 3.15% |
AbbVie Inc | Equity | ₹4.81 Cr | 3.01% |
Torrent Pharmaceuticals Ltd | Equity | ₹4.56 Cr | 2.85% |
Fortis Healthcare Ltd | Equity | ₹3.93 Cr | 2.46% |
Aurobindo Pharma Ltd | Equity | ₹3.71 Cr | 2.33% |
Mankind Pharma Ltd | Equity | ₹3.42 Cr | 2.14% |
Novo Nordisk AS ADR | Equity | ₹3.02 Cr | 1.89% |
Merck & Co Inc | Equity | ₹3.01 Cr | 1.88% |
Abbott Laboratories | Equity | ₹2.81 Cr | 1.76% |
Novartis AG ADR | Equity | ₹2.76 Cr | 1.73% |
Zydus Lifesciences Ltd | Equity | ₹2.73 Cr | 1.71% |
Laurus Labs Ltd | Equity | ₹2.56 Cr | 1.60% |
Glenmark Pharmaceuticals Ltd | Equity | ₹2.52 Cr | 1.58% |
Alkem Laboratories Ltd | Equity | ₹2.45 Cr | 1.54% |
Ipca Laboratories Ltd | Equity | ₹2.44 Cr | 1.53% |
Thermo Fisher Scientific Inc | Equity | ₹2.43 Cr | 1.52% |
Intuitive Surgical Inc | Equity | ₹2.23 Cr | 1.40% |
Amgen Inc | Equity | ₹2.17 Cr | 1.36% |
Biocon Ltd | Equity | ₹1.7 Cr | 1.07% |
Danaher Corp | Equity | ₹1.7 Cr | 1.06% |
Gilead Sciences Inc | Equity | ₹1.69 Cr | 1.06% |
Stryker Corp | Equity | ₹1.63 Cr | 1.02% |
Vertex Pharmaceuticals Inc | Equity | ₹1.6 Cr | 1.00% |
Piramal Pharma Ltd | Equity | ₹1.58 Cr | 0.99% |
Syngene International Ltd | Equity | ₹1.55 Cr | 0.97% |
Medtronic PLC | Equity | ₹1.47 Cr | 0.92% |
Suven Pharmaceuticals Ltd | Equity | ₹1.46 Cr | 0.92% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.46 Cr | 0.91% |
Ajanta Pharma Ltd | Equity | ₹1.42 Cr | 0.89% |
Narayana Hrudayalaya Ltd | Equity | ₹1.41 Cr | 0.88% |
Gland Pharma Ltd | Equity | ₹1.4 Cr | 0.87% |
Global Health Ltd | Equity | ₹1.15 Cr | 0.72% |
Regeneron Pharmaceuticals Inc | Equity | ₹0.89 Cr | 0.56% |
Becton Dickinson & Co | Equity | ₹0.84 Cr | 0.53% |
Net Receivables/(Payables) | Cash | ₹0.55 Cr | 0.35% |
Agilent Technologies Inc | Equity | ₹0.43 Cr | 0.27% |
IQVIA Holdings Inc | Equity | ₹0.42 Cr | 0.26% |
Illumina Inc | Equity | ₹0.17 Cr | 0.11% |
Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹0.09 Cr | 0.06% |
Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Large Cap Stocks
33.22%
Mid Cap Stocks
30.39%
Small Cap Stocks
5.98%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹159.13 Cr | 99.60% |
Standard Deviation
This fund
13.13%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.71
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since October 2021
Since February 2021
ISIN INF754K01LV5 | Expense Ratio 0.50% | Exit Load No Charges | Fund Size ₹160 Cr | Age 4 years 5 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark MSCI Ind Dom & Wld HealthC 45 NR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
SBI BSE PSU Bank Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹8.42 Cr | - |
SBI BSE PSU Bank Index Fund Regular Growth Very High Risk | 0.8% | 0.0% | ₹8.42 Cr | - |
SBI BSE PSU Bank ETF Very High Risk | 0.3% | - | ₹205.39 Cr | - |
Tata BSE Quality Index Fund Direct Growth Very High Risk | - | 0.0% | - | - |
Tata BSE Quality Index Fund Regular Growth Very High Risk | - | 0.0% | - | - |
HDFC Nifty Top 20 Equal Weight Index Fund Direct Growth Very High Risk | - | 0.0% | ₹70.51 Cr | - |
HDFC Nifty Top 20 Equal Weight Index Fund Regular Growth Very High Risk | - | 0.0% | ₹70.51 Cr | - |
Kotak Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.3% | 0.0% | ₹7.20 Cr | - |
Kotak Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹7.20 Cr | - |
Mirae Asset BSE 200 Equal Weight ETF Very High Risk | - | - | ₹14.21 Cr | - |
Total AUM
₹1,60,443 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Your principal amount will be at Very High Risk
EquityIndex FundsVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹160 Cr
Expense Ratio
0.50%
ISIN
INF754K01LV5
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+11.88%
— (Cat Avg.)
3 Years
+14.38%
— (Cat Avg.)
Since Inception
+15.63%
— (Cat Avg.)
Equity | ₹159.13 Cr | 99.60% |
Others | ₹0.64 Cr | 0.40% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹20.23 Cr | 12.66% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹10.21 Cr | 6.39% |
Cipla Ltd | Equity | ₹9.17 Cr | 5.74% |
Eli Lilly and Co | Equity | ₹8.83 Cr | 5.53% |
Dr Reddy's Laboratories Ltd | Equity | ₹8.2 Cr | 5.14% |
Divi's Laboratories Ltd | Equity | ₹8.19 Cr | 5.12% |
Apollo Hospitals Enterprise Ltd | Equity | ₹8 Cr | 5.01% |
Lupin Ltd | Equity | ₹5.73 Cr | 3.58% |
Johnson & Johnson | Equity | ₹5.03 Cr | 3.15% |
AbbVie Inc | Equity | ₹4.81 Cr | 3.01% |
Torrent Pharmaceuticals Ltd | Equity | ₹4.56 Cr | 2.85% |
Fortis Healthcare Ltd | Equity | ₹3.93 Cr | 2.46% |
Aurobindo Pharma Ltd | Equity | ₹3.71 Cr | 2.33% |
Mankind Pharma Ltd | Equity | ₹3.42 Cr | 2.14% |
Novo Nordisk AS ADR | Equity | ₹3.02 Cr | 1.89% |
Merck & Co Inc | Equity | ₹3.01 Cr | 1.88% |
Abbott Laboratories | Equity | ₹2.81 Cr | 1.76% |
Novartis AG ADR | Equity | ₹2.76 Cr | 1.73% |
Zydus Lifesciences Ltd | Equity | ₹2.73 Cr | 1.71% |
Laurus Labs Ltd | Equity | ₹2.56 Cr | 1.60% |
Glenmark Pharmaceuticals Ltd | Equity | ₹2.52 Cr | 1.58% |
Alkem Laboratories Ltd | Equity | ₹2.45 Cr | 1.54% |
Ipca Laboratories Ltd | Equity | ₹2.44 Cr | 1.53% |
Thermo Fisher Scientific Inc | Equity | ₹2.43 Cr | 1.52% |
Intuitive Surgical Inc | Equity | ₹2.23 Cr | 1.40% |
Amgen Inc | Equity | ₹2.17 Cr | 1.36% |
Biocon Ltd | Equity | ₹1.7 Cr | 1.07% |
Danaher Corp | Equity | ₹1.7 Cr | 1.06% |
Gilead Sciences Inc | Equity | ₹1.69 Cr | 1.06% |
Stryker Corp | Equity | ₹1.63 Cr | 1.02% |
Vertex Pharmaceuticals Inc | Equity | ₹1.6 Cr | 1.00% |
Piramal Pharma Ltd | Equity | ₹1.58 Cr | 0.99% |
Syngene International Ltd | Equity | ₹1.55 Cr | 0.97% |
Medtronic PLC | Equity | ₹1.47 Cr | 0.92% |
Suven Pharmaceuticals Ltd | Equity | ₹1.46 Cr | 0.92% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.46 Cr | 0.91% |
Ajanta Pharma Ltd | Equity | ₹1.42 Cr | 0.89% |
Narayana Hrudayalaya Ltd | Equity | ₹1.41 Cr | 0.88% |
Gland Pharma Ltd | Equity | ₹1.4 Cr | 0.87% |
Global Health Ltd | Equity | ₹1.15 Cr | 0.72% |
Regeneron Pharmaceuticals Inc | Equity | ₹0.89 Cr | 0.56% |
Becton Dickinson & Co | Equity | ₹0.84 Cr | 0.53% |
Net Receivables/(Payables) | Cash | ₹0.55 Cr | 0.35% |
Agilent Technologies Inc | Equity | ₹0.43 Cr | 0.27% |
IQVIA Holdings Inc | Equity | ₹0.42 Cr | 0.26% |
Illumina Inc | Equity | ₹0.17 Cr | 0.11% |
Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹0.09 Cr | 0.06% |
Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Large Cap Stocks
33.22%
Mid Cap Stocks
30.39%
Small Cap Stocks
5.98%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹159.13 Cr | 99.60% |
Standard Deviation
This fund
13.13%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.71
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since October 2021
Since February 2021
ISIN INF754K01LV5 | Expense Ratio 0.50% | Exit Load No Charges | Fund Size ₹160 Cr | Age 4 years 5 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark MSCI Ind Dom & Wld HealthC 45 NR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
SBI BSE PSU Bank Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹8.42 Cr | - |
SBI BSE PSU Bank Index Fund Regular Growth Very High Risk | 0.8% | 0.0% | ₹8.42 Cr | - |
SBI BSE PSU Bank ETF Very High Risk | 0.3% | - | ₹205.39 Cr | - |
Tata BSE Quality Index Fund Direct Growth Very High Risk | - | 0.0% | - | - |
Tata BSE Quality Index Fund Regular Growth Very High Risk | - | 0.0% | - | - |
HDFC Nifty Top 20 Equal Weight Index Fund Direct Growth Very High Risk | - | 0.0% | ₹70.51 Cr | - |
HDFC Nifty Top 20 Equal Weight Index Fund Regular Growth Very High Risk | - | 0.0% | ₹70.51 Cr | - |
Kotak Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.3% | 0.0% | ₹7.20 Cr | - |
Kotak Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹7.20 Cr | - |
Mirae Asset BSE 200 Equal Weight ETF Very High Risk | - | - | ₹14.21 Cr | - |
Total AUM
₹1,60,443 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments